(Q40142279)

17 September 2017

Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm (English)

1 reference

17 September 2017

0 references

1 reference

Anthony P Raphael

2

0 references

Natalie Prow

object named as

Natalie A Prow

7

0 references

Tarl W. Prow

object named as

Tarl W Prow

10

0 references

Andreas Suhrbier

11

object named as

Andreas Suhrbier

1 reference

17 September 2017

5

Joy Gardner

1 reference

17 September 2017

1

Penny A Rudd

1 reference

17 September 2017

3

Miko Yamada

1 reference

17 September 2017

4

Kaitlin L Nufer

1 reference

17 September 2017

Thuy T T Le

6

1 reference

17 September 2017

Nhung Dang

8

1 reference

17 September 2017

Wayne A Schroder

9

1 reference

17 September 2017

language of work or name

English

0 references

publication date

18 August 2015

1 reference

17 September 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

17 September 2017

33

1 reference

17 September 2017

39

1 reference

17 September 2017

5172-5180

1 reference

Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Cutaneous immunization: an evolving paradigm in influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Novel strategies for effective transdermal drug delivery: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Microneedles for drug and vaccine delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Elongate microparticles for enhanced drug delivery to ex vivo and in vivo pig skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

High Aspect Ratio Elongated Microparticles for Enhanced Topical Drug Delivery in Human Volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Arthritogenic alphaviruses--an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Arrival of chikungunya virus in the new world: prospects for spread and impact on public health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

The threat of chikungunya in Oceania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Infectious diseases. Crippling virus set to conquer Western Hemisphere

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Effective chikungunya virus-like particle vaccine produced in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Chikungunya virus arthritis in adult wild-type mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Chikungunya disease outbreak, Reunion Island.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Arbovirus of marine mammals: a new alphavirus isolated from the elephant seal louse, Lepidophthirus macrorhini.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Targeting the skin for microneedle delivery of influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Variation in epidermal morphology in human skin at different body sites as measured by reflectance confocal microscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Isopropyl alcohol skin antisepsis does not reduce incidence of infection following insulin injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Pathogen recognition and development of particulate vaccines: does size matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.099

10.1016/J.VACCINE.2015.07.099

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference